{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:14:06Z","timestamp":1787066046380,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014607","name":"Royal Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40264-026-01650-0","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:42:05Z","timestamp":1775810525000},"page":"705-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Aishwarya N.","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Mallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneeta","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel J.","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim P.","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SAFESIG\u2013GP Primary Health Network (PHN) Collaboration Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Swann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Giddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Daraganova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02450-w","volume":"23","author":"KJ Li","year":"2021","unstructured":"Li KJ, Semenov D, Turk M, Pope J. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23:82. https:\/\/doi.org\/10.1186\/s13075-021-02450-w.","journal-title":"Arthritis Res Ther"},{"key":"1650_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jvs.2005.12.043","volume":"43","author":"II Pipinos","year":"2006","unstructured":"Pipinos II, Hopp R, Edwards WD, Radio SJ. Giant-cell temporal arteritis in a 17-year-old male. J Vasc Surg. 2006;43:1053\u20135. https:\/\/doi.org\/10.1016\/j.jvs.2005.12.043.","journal-title":"J Vasc Surg"},{"key":"1650_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00002281-200201000-00002","volume":"14","author":"SM Levine","year":"2002","unstructured":"Levine SM, Hellmann DB. Giant cell arteritis. Curr Opin Rheumatol. 2002;14:3\u201310. https:\/\/doi.org\/10.1097\/00002281-200201000-00002.","journal-title":"Curr Opin Rheumatol"},{"key":"1650_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1964","author":"K Lazarewicz","year":"2019","unstructured":"Lazarewicz K, Watson P. Giant cell arteritis. Br Med J. 2019. https:\/\/doi.org\/10.1136\/bmj.l1964.","journal-title":"Br Med J"},{"key":"1650_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21608","volume":"14","author":"CS Greb","year":"2022","unstructured":"Greb CS, Aouhab Z, Sisbarro D, Panah E. A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence? Cureus. 2022;14:e21608. https:\/\/doi.org\/10.7759\/cureus.21608.","journal-title":"Cureus"},{"key":"1650_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s10067-021-06041-7","volume":"41","author":"AM Anzola","year":"2022","unstructured":"Anzola AM, Trives L, Mart\u00ednez-Barrio J, Pinilla B, \u00c1lvaro-Gracia JM, Molina-Collada J. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech\/Pfizer) vaccine: a double-edged sword? Clin Rheumatol. 2022;41:1623\u20135. https:\/\/doi.org\/10.1007\/s10067-021-06041-7.","journal-title":"Clin Rheumatol"},{"key":"1650_CR7","unstructured":"Australian Bureau of Statistics, National, State and Territory Population. 2024. https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release. Accessed 12 Sep 2025."},{"key":"1650_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2100173","volume":"18","author":"JP Buttery","year":"2022","unstructured":"Buttery JP, Clothier H. Information systems for vaccine safety surveillance. Hum Vaccin Immunother. 2022;18:2100173. https:\/\/doi.org\/10.1080\/21645515.2022.2100173.","journal-title":"Hum Vaccin Immunother"},{"key":"1650_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2052701","volume":"18","author":"SF Gordon","year":"2022","unstructured":"Gordon SF, Virah Sawmy E, Duckworth E, Wolthuizen M, Clothier HJ, Chea M, et al. Victorian Specialist Immunisation Services (VicSIS) \u2013 bolstering adult clinics for COVID-19 vaccines. Hum Vacc Immunother. 2022;18:2052701. https:\/\/doi.org\/10.1080\/21645515.2022.2052701.","journal-title":"Hum Vacc Immunother"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40264-017-0520-7","volume":"40","author":"HJ Clothier","year":"2017","unstructured":"Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of \u201cSAEFVIC\u201d, a pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40:483\u201395. https:\/\/doi.org\/10.1007\/s40264-017-0520-7.","journal-title":"Drug Saf"},{"key":"1650_CR11","unstructured":"Pearce C, McLeod A, Rinehart N, Ferrigi J, Shearer M, What a comprehensive, integrated data strategy looks like: the population level analysis and reporting (polar) program, In (Eds.), MedInfo 2019: Health and Wellbeing e-Networks for All, IOS Press; 2019, 303\u20137."},{"key":"1650_CR12","volume":"121","author":"K Donnelly","year":"2006","unstructured":"Donnelly K. SNOMED-CT: the advanced terminology and coding system for eHealth. Stud Health Technol Inform. 2006;121:279.","journal-title":"Stud Health Technol Inform"},{"key":"1650_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anzjph.2024.100188","volume":"48","author":"HJ Morgan","year":"2024","unstructured":"Morgan HJ, Clothier HJ, Witowski P, Boyd JH, Kattan GS, Dimaguila GL, et al. Establishing the vaccine safety health link: a large, linked data resource for the investigation of vaccine safety concerns. Aust N Z J Public Health. 2024;48:100188. https:\/\/doi.org\/10.1016\/j.anzjph.2024.100188.","journal-title":"Aust N Z J Public Health"},{"key":"1650_CR14","unstructured":"Department of Health Victoria. Notifiable infectious diseases, conditions and micro-organisms. https:\/\/www.health.vic.gov.au\/infectious-diseases\/notifiable-infectious-diseases-conditions-and-micro-organisms. Accessed 12 Sep 2025."},{"key":"1650_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224702","volume":"14","author":"HJ Clothier","year":"2019","unstructured":"Clothier HJ, Lawrie J, Russell MA, Kelly H, Buttery JP. Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia. PLoS ONE. 2019;14:e0224702. https:\/\/doi.org\/10.1371\/journal.pone.0224702.","journal-title":"PLoS ONE"},{"key":"1650_CR16","unstructured":"R Core Team, R: a language and environment for statistical computing. 2021. https:\/\/www.R-project.org. Accessed 1 June 2025."},{"key":"1650_CR17","unstructured":"Yonas Ghebremichael Weldeselassie HW, Paddy Farrington, The self-controlled case series method. 2024. https:\/\/cran.r-project.org\/web\/packages\/SCCS\/SCCS.pdf. Accessed 6 Aug 2025."},{"key":"1650_CR18","doi-asserted-by":"crossref","unstructured":"Konrad Stopsack TG, Risks: estimate risk ratios and risk differences using regression. 2023. https:\/\/cran.r-project.org\/web\/packages\/risks\/index.html. Accessed 20 Mar 2025.","DOI":"10.32614\/CRAN.package.risks"},{"key":"1650_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10059-009-0015-1","volume":"27","author":"SM Kang","year":"2009","unstructured":"Kang SM, Compans RW. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells. 2009;27:5\u201314. https:\/\/doi.org\/10.1007\/s10059-009-0015-1.","journal-title":"Mol Cells"},{"key":"1650_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70020","volume":"32","author":"E Lim","year":"2025","unstructured":"Lim E, Kim YH, Jeong NY, Kim SH, Won H, Bae JS, et al. The association between acute transverse myelitis and COVID-19 vaccination in Korea: self-controlled case series study. Eur J Neurol. 2025;32:e70020. https:\/\/doi.org\/10.1111\/ene.70020.","journal-title":"Eur J Neurol"},{"key":"1650_CR21","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2024.01.099","volume":"42","author":"HJ Morgan","year":"2024","unstructured":"Morgan HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, Buttery JP. Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination \u2013 a self-controlled case series analysis. Vaccine. 2024;42:2212\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.099.","journal-title":"Vaccine"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","volume":"42","author":"K Faksova","year":"2024","unstructured":"Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, et al. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42:2200\u201311. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100.","journal-title":"Vaccine"},{"key":"1650_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59122127","author":"K Yoshimoto","year":"2023","unstructured":"Yoshimoto K, Kaneda S, Asada M, Taguchi H, Kawashima H, Yoneima R, et al. Giant cell arteritis after COVID-19 vaccination with long-term follow-up: a case report and review of the literature. Medicina (Kaunas). 2023. https:\/\/doi.org\/10.3390\/medicina59122127.","journal-title":"Medicina (Kaunas)"},{"key":"1650_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105282","volume":"89","author":"S Cadiou","year":"2022","unstructured":"Cadiou S, Perdriger A, Ardois S, Albert JD, Berthoud O, Lescoat A, et al. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: \u201cCan SARS-CoV-2 trigger relapse of polymyalgia rheumatica?\u201d by Manzo et al. Joint Bone Spine 2021;88:105150. Joint Bone Spine. 2022;89:105282. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105282.","journal-title":"Joint Bone Spine"},{"key":"1650_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3899\/jrheum.210724","volume":"49","author":"A Sauret","year":"2022","unstructured":"Sauret A, Stievenart J, Smets P, Olagne L, Guelon B, Auma\u00eetre O, et al. Case of giant cell arteritis after SARS-CoV-2 vaccination: a particular phenotype? J Rheumatol. 2022;49:120. https:\/\/doi.org\/10.3899\/jrheum.210724.","journal-title":"J Rheumatol"},{"key":"1650_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25388","volume":"14","author":"C Xia","year":"2022","unstructured":"Xia C, Edwards R, Omidvar B. A case of giant cell arteritis with a normal erythrocyte sedimentation rate (ESR) post ChAdOx1 nCoV-19 vaccination. Cureus. 2022;14:e25388. https:\/\/doi.org\/10.7759\/cureus.25388.","journal-title":"Cureus"},{"key":"1650_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020434","author":"L Lo Sardo","year":"2023","unstructured":"Lo Sardo L, Parisi S, Ditto MC, De Giovanni R, Maletta F, Grimaldi S, et al. New onset of giant cell arteritis following ChAdOx1-S (Vaxevria(\u00ae)) vaccine administration. Vaccines (Basel). 2023. https:\/\/doi.org\/10.3390\/vaccines11020434.","journal-title":"Vaccines (Basel)"},{"key":"1650_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20824","volume":"186","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Krogias C, Tischoff I, Tannapfel A, Gold R, Susok L. Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination. Br J Dermatol. 2022;186:e83. https:\/\/doi.org\/10.1111\/bjd.20824.","journal-title":"Br J Dermatol"},{"key":"1650_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/03009742.2021.1961401","volume":"51","author":"A Mejren","year":"2022","unstructured":"Mejren A, S\u00f8rensen CM, Gormsen LC, Tougaard RS, Nielsen BD. Large-vessel giant cell arteritis after COVID-19 vaccine. Scand J Rheumatol. 2022;51:154\u20135. https:\/\/doi.org\/10.1080\/03009742.2021.1961401.","journal-title":"Scand J Rheumatol"},{"key":"1650_CR30","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1097\/wno.0000000000001570","volume":"43","author":"SA Che","year":"2023","unstructured":"Che SA, Lee KY, Yoo YJ. Bilateral ischemic optic neuropathy from giant cell arteritis following COVID-19 vaccination. J Neuroophthalmol. 2023;43:e107\u20138. https:\/\/doi.org\/10.1097\/wno.0000000000001570.","journal-title":"J Neuroophthalmol"},{"key":"1650_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11739-021-02908-4","volume":"17","author":"M Gilio","year":"2022","unstructured":"Gilio M, De Stefano G. Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine. Intern Emerg Med. 2022;17:1239\u201341. https:\/\/doi.org\/10.1007\/s11739-021-02908-4.","journal-title":"Intern Emerg Med"},{"key":"1650_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/qjmed\/hcac171","volume":"115","author":"DK Ishizuka","year":"2022","unstructured":"Ishizuka DK, Katayama K, Ohira Y. Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination. Q J Med. 2022;115:621\u20132. https:\/\/doi.org\/10.1093\/qjmed\/hcac171.","journal-title":"Q J Med"},{"key":"1650_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000033948","volume":"102","author":"H Wakabayashi","year":"2023","unstructured":"Wakabayashi H, Iwayanagi M, Sakai D, Sugiura Y, Hiruta N, Matsuzawa Y, et al. Development of giant cell arteritis after vaccination against SARS-CoV2: a case report and literature review. Medicine (Baltimore). 2023;102:e33948. https:\/\/doi.org\/10.1097\/md.0000000000033948.","journal-title":"Medicine (Baltimore)"},{"key":"1650_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/mrcr\/rxae042","volume":"9","author":"S-i Ohmura","year":"2024","unstructured":"Ohmura S-i, Yonezawa H, Yukishima T, Gohto Y, Obana A. New onset of giant cell arteritis with ischaemic optic neuropathy following the seventh dose of COVID-19 mRNA vaccination: a case report and literature review. Mod Rheumatol Case Rep. 2024;9:131\u20136. https:\/\/doi.org\/10.1093\/mrcr\/rxae042.","journal-title":"Mod Rheumatol Case Rep"},{"key":"1650_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102732","volume":"20","author":"E Liozon","year":"2021","unstructured":"Liozon E, Parreau S, Filloux M, Dumonteil S, Gondran G, Bezanahary H, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev. 2021;20:102732. https:\/\/doi.org\/10.1016\/j.autrev.2020.102732.","journal-title":"Autoimmun Rev"},{"key":"1650_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa647","volume":"8","author":"WA Agger","year":"2021","unstructured":"Agger WA, Deviley JA, Borgert AJ, Rasmussen CM. Increased incidence of giant cell arteritis after introduction of a live varicella zoster virus vaccine. Open Forum Infect Dis. 2021;8:ofaa647. https:\/\/doi.org\/10.1093\/ofid\/ofaa647.","journal-title":"Open Forum Infect Dis"},{"key":"1650_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080848","author":"GT Rijkers","year":"2021","unstructured":"Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, et al. Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2 vaccines. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9080848.","journal-title":"Vaccines"},{"key":"1650_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009128","volume":"16","author":"T Patra","year":"2020","unstructured":"Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, et al. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. PLoS Pathog. 2020;16:e1009128. https:\/\/doi.org\/10.1371\/journal.ppat.1009128.","journal-title":"PLoS Pathog"},{"key":"1650_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/rheumatology\/keab756","volume":"61","author":"C Mettler","year":"2021","unstructured":"Mettler C, Jonville-Bera A-P, Grandvuillemin A, Treluyer J-M, Terrier B, Chouchana L. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology. 2021;61:865\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab756.","journal-title":"Rheumatology"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01650-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:16:49Z","timestamp":1778483809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01650-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01650-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Access to SAEFVIC data conforms to the function as\u00a0public health\u00a0vaccine safety surveillance approved by the Royal Children\u2019s Hospital Health Research Ethics Committee (HREC) as a registered database #96896.\u00a0Ethics approval was granted by the Monash HREC (RES-18-0000-232A) for GP data, the RCH Melbourne HREC (79964) for linked data, and the Royal Australian College of General Practitioners National Research and Evaluation Ethics Committee (RACGP NREEC) (17-008) for POLAR.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A waiver of consent was granted by the respective health research ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"De-identified information from the consumer who initiated this investigation is included with their consent. Data used in the three analyses were covered by ethics approvals granting a waiver of individual consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The data used in the spontaneous reporting dataset, SCCS analysis for GP data hosted by Outcome Health and for the linked dataset by the Centre for Victorian Data Linkage were used under ethics for the current study and therefore are not publicly available, and authors are not permitted to share raw data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The codes are hosted in secure environments and cannot be publicly shared. It can be made available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.S., H.C. and J.B. conceptualised the study. A.S. had access to general practice data and J.M. to linked hospital data and took responsibility for the integrity of the data and the accuracy of the analysis. A.S., J.M. and D.H. were involved in statistical analysis. A.S., J.M. and D.H., along with all authors, contributed to data acquisition, analysis, and interpretation. A.S. wrote the initial draft of the manuscript. All authors critically revised the manuscript for important intellectual content. A.S. provided administrative, technical or material support. J.B. and H.C. supervised the study. All authors revised and approved the submitted version. A.S., H.C. and J.B. had final responsibility for the decision to submit for publication. All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}